Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN G POTASSIUM versus UNASYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN G POTASSIUM versus UNASYN.
PENICILLIN G POTASSIUM vs UNASYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal: inhibits transpeptidases (penicillin-binding proteins) involved in bacterial cell wall synthesis, leading to cell lysis.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs); sulbactam is a beta-lactamase inhibitor that prevents degradation of ampicillin by beta-lactamases.
1-4 million units IV every 4-6 hours; maximum 24 million units/day
3 g (ampicillin 2 g + sulbactam 1 g) IV every 6 hours; total daily dose of sulbactam not to exceed 4 g.
None Documented
None Documented
0.5-1 hour in normal renal function; prolonged to 3-10 hours in anuria/end-stage renal disease.
Ampicillin: ~1 hour (normal renal function); sulbactam: ~1-1.4 hours (normal renal function); prolonged in renal impairment (ampicillin up to 20 hours, sulbactam up to 10-15 hours in anuria).
Renal (60-90% as unchanged drug via tubular secretion and glomerular filtration); biliary (minor, <10%); fecal (minimal, <5%).
Renal: ampicillin (~75-90% unchanged) and sulbactam (~75-85% unchanged); biliary/fecal: minimal (<5% for each component).
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic